Bicara Therapeutics Inc.
Bicara Therapeutics Inc. (Nasdaq: BCAX) is a clinical-stage biopharmaceutical company developing bifunctional therapies for solid tumors. Its lead candidate, ficerafusp alfa, combines an EGFR-directed antibody with a TGF-β ligand trap, designed to target tumors while inhibiting immunosuppressive signaling in the tumor… From the company’s description.
In fiscal 2025, Bicara Therapeutics Inc. reported a net loss of $137.95M. Operations used $106.83M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Bicara Therapeutics Inc. does
In the company’s own words
Bicara Therapeutics Inc. (Nasdaq: BCAX) is a clinical-stage biopharmaceutical company developing bifunctional therapies for solid tumors. Its lead candidate, ficerafusp alfa, combines an EGFR-directed antibody with a TGF-β ligand trap, designed to target tumors while inhibiting immunosuppressive signaling in the tumor microenvironment. The candidate is being studied primarily in head and neck squamous cell carcinoma, including in combination with pembrolizumab in a Phase 2/3 pivotal trial for first-line recurrent or metastatic HPV-negative disease; the company is also evaluating it in colorectal, cutaneous squamous cell and anal squamous cell cancers. Bicara’s development work includes clinical trials and research programs, rather than reportable operating segments. Ficerafusp alfa is licensed from Biocon, and the company collaborates with MSD, which supplies pembrolizumab for combination clinical studies. Its website is https://www.bicaratherapeutics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 2023658
- SIC
- 2834
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Bicara Therapeutics Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Bicara Therapeutics Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Bicara Therapeutics Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Bicara Therapeutics Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Bicara Therapeutics Inc.'s last four quarterly filings that the numbers alone won't show?”